Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 696-003-5 | CAS number: 924726-92-1
Based upon the outcome of a read across approach GSK2609973A is not expected to be cacinogenic.
A package of occupational toxicology tests and pharmacological screening assays have been completed for GSK2609973A. Functional receptor screening tests have also been conducting with this compound in order to understand its potential for interaction with the human glucocorticoid receptor.
The conclusion of the assessment relies primarily upon read across from structurally-related substances with the package of occupational toxicology tests providing data to support this approach. This is consistent with international guidelines for read across of toxicological data (1, 2).
1. European Chemicals Agency, Guidance on information requirements and chemical safety assessment 1. Chapter R.6: QSARs and grouping of chemicals, Guidance for the Implementation of REACH.May 2008
2. OECD, Series on Testing and Assessment, Number 80, Guidance on Grouping of Chemicals, September 2007
Taking account of the small package of studies with GSK2609973A and close structural similarity to substances for which a more complete dataset exists, it is considered justified to use a read-across approach to address any outstanding data-gaps for this material.
Only a limited number of glucocorticoids have been tested for carcinogenicity, but some have produced an increase in hepatocellular tumours when tested via the oral route. This is considered to be a consequence of pharmacological activity at high doses for a prolonged period and probably not of relevance to typical occupational exposure. A single study reports an increase incidence of rare bone tumours in Sprague Dawley rats following two years dietary dosing at 0.25 mg/kg/day with Deflazacort, but this was not seen in a parallel study in mice. Studies conducted via the inhalation route with the potent glucocorticoids fluticasone propionate and fluticasone furoate were negative for tumourigenic effect.
Based upon the outcome of this read across approach GSK2609973A is not expected to be cacinogenic.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again